Table 3.
Baseline and 6th month clinical characteristics of patients treated with tocilizumab.
| Baseline (mean ± SD) (Median, range) | 6th month (mean ± SD) (Median, range) | p value | |
|---|---|---|---|
| Visual Acuity (log MAR) | 0.46 ± 0.46 (0.3, 0–1.2) | 0.43 ± 0.45 (0.3, 0-1.2) | 0.122a |
| AC cells (0–4) | 0.27 ± 0.65 (0, 0–2) | 0.0 ± 0.00 (0) | 0.142b |
| AC flare (0–4) | 1.27 ± 0.60 (1.5, 0–2) | 0.65 ± 0.24 (0.5, 0-1) | 0.001b |
| Vitreous haze (0–4) | 0.14 ± 0.32 (0, 0–1) | 0.22 ± 0.51 (0, 0-1) | 0.723b |
| CST (μm) | 353.2 ± 97.3 (323, 251-524) | 299.1 ± 36.8 (289, 250-373) | 0.010a |
| FA score | 11.6 ± 4.4 (12, 4-17) | 5.8 ± 3.9 (6, 0-14) | 0.001a |
| Presence of CMO | 45.5% (5) | 9.1% (1) | 0.038c |
| Optic disc involvement | 90.9% (10) | 63.6% (7) | 0.073c |
SD Standard deviation, AC Anterior chamber, CST Central subfield thickness, FA Fluorescein angiography, CME Cystoid macular oedema.
aGEE with linear regression model.
bGEE with ordinal logistic model.
cGEE with binary logistic model.
Bold values represent significant p value.